
Pfizer set to develop new $200 million site
pharmafile | November 23, 2016 | News story | Manufacturing and Production, Research and Development |ย ย Pfizer, manufacturing and productionย
Pfizer plans to expand its operations in St. Louis, Missouri, by developing a $200 million facility in Chesterfield. The site will particularly focus upon research and development, creating more than 80 jobs and retaining 450 positions that already exist in the area.
Pfizer have held R&D facilities in the area for 13 years but this recent investment will see around 625 people employed on the new site. The facility will focus on the development biologic therapies and vaccines for clinical trials.
โMissouri is an important part of Pfizerโs R&D network, and weโre proud of the world-class employee base weโve built here,โ John Ludwig, senior vice president of BioTherapeutics Research for Pfizer, said in a statement. โThanks to the support weโve received from the state of Missouri, St. Louis County and Chesterfield, our new St. Louis laboratory facility will provide the right location and space as we continue to evolve our business over the coming years.โ
Pfizer will potentially be able to receive an incentive package from the state for the construction of the site. Depending on job creation figures, it could receive as much as $5 million of the cost of the facility from the state and a further $800,000 if it provides a specified level of training to staff.
Construction of the site will begin in the middle of 2017, with completion of the site aiming to be sometime in 2020.
Related Content

Rotzinger launches modular filling and capping platform for over-the-counter products
Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …
NICE recommends Pfizerโs new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21stย May 2025ย โย Pfizer Ltd announced today that the National Institute for Health and Care …

Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …






